Drug Profile
Research programme: gene therapies - Adverum Biotechnologies
Alternative Names: AAV.7m8-ranibizumab; ADVM-032; ANN-003; ANN-004Latest Information Update: 26 Nov 2018
Price :
$50
*
At a glance
- Originator Weill Cornell Medical College
- Developer Adverum Biotechnologies; Weill Cornell Medical College
- Class Antiallergics; Eye disorder therapies; Gene therapies; Heart failure therapies; Hepatoprotectants
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cardiomyopathies; Hypersensitivity; Wet age-related macular degeneration
Most Recent Events
- 26 Nov 2018 Discontinued - Preclinical for Hypersensitivity in France (unspecified route)
- 26 Nov 2018 Discontinued - Preclinical for Hypersensitivity in USA (unspecified route)
- 26 Nov 2018 Discontinued - Preclinical for Wet age-related macular degeneration in USA (Intravitreous)